Meeting
2014 ASCO Annual Meeting
A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.
Authors
Rita Nanda
The University of Chicago, Chicago, IL
Rita Nanda , Elizabeth R. Plimack , Elizabeth Claire Dees , Shilpa Gupta , Raanan Berger , Aymen Elfiky , Lajos Pusztai , Laurence Buisseret , Ravit Geva , Sara I Pai , Kumudu Pathiraja , Robert Iannone , Christine Gause , Holly Brown , Jennifer Houp , Jonathan D. Cheng , Laura Quan Man Chow
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01848834
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3119)
DOI
10.1200/jco.2014.32.15_suppl.tps3119
Abstract #
TPS3119
Poster Bd #
182A
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2019 ASCO Annual Meeting
Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study.
First Author: Junho Kang
Poster
2014 ASCO Annual Meeting
A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.
First Author: David F. McDermott
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang